Comparison of the syringeability of a fixed combination of florfenicol and meloxicam with florfenicol-based products commonly used in bovine respiratory disease (BRD)

Syringeability is a direct measurement of the performance of the formulation of any injectable product. It is a key-product criterion strongly connected to compliance and user safety. For calves with bovine respiratory disease (BRD), a better syringeability can also positively contribute to reduce the stress associated with the administration of the product. On the other hand, some florfenicol-based products are known for having a poor syringeability. This study was therefore designed to compare the syringeability of a new fixed combination of florfenicol and meloxicam: Zeleris® (florfenicol 400 mg/mL and meloxicam 5 mg/mL, Ceva) with three florfenicol-based veterinary products commonly used in BRD: Resflor® (florfenicol 300 mg/mL and flunixin meglumine 16.5 mg/mL, MSD), Nuflor®300 (florfenicol 300 mg/mL, MSD), Florkem® (florfenicol 300 mg/mL, Ceva).

The results of this study clearly demonstrated the high syringeability of the new fixed combination of florfenicol and meloxicam (Zeleris®). Zeleris® syringeability was better than the other florfenicol-based products both at 5°C and at room temperature (figure 1 and 2). The superior performances of Zeleris® may be explained by the various excipients used in its formulation.